The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).
 
Samuel J Klempner
Stock and Other Ownership Interests - Nuvalent, Inc.; TP Therapeutics
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Coherus Biosciences; Daiichi Sankyo/UCB Japan; Exact Sciences; Merck; Mersana; Novartis; Sanofi/Aventis; SERVIER
Research Funding - BeiGene (Inst); Leap Therapeutics (Inst); Silverback Therapeutics (Inst)
Other Relationship - Clinical Care Options; NCCN; Research to Practice
 
Bassam Bassam Sonbol
Research Funding - Lilly (Inst); Taiho Oncology (Inst)
 
Zev A. Wainberg
Consulting or Advisory Role - Amgen; Arcus Biosciences; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; QED Therapeutics; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Hope Elizabeth Uronis
Employment - GeneCentric (I)
Stock and Other Ownership Interests - GeneCentric (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex
Research Funding - Adaptimmune (Inst); Arcus Biosciences (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Vi Kien Chiu
Research Funding - Alkermes (Inst); Arcus Biosciences (Inst); BioNTech SE (Inst); Incyte (Inst); Intra-Immusg (Inst); Leap Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Seattle Genetics/Astellas (Inst); TyrNovo (Inst)
 
Aaron James Scott
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Exelixis; Pfizer; QED Therapeutics
Research Funding - Exelixis; Five Prime Therapeutics; Genentech; Incyte; Merck
Travel, Accommodations, Expenses - Exelixis; QED Therapeutics
 
Syma Iqbal
Honoraria - BeiGene
Consulting or Advisory Role - AstraZeneca; BMS; BMS; Daiichi Sankyo/Astra Zeneca; Merck
 
Mohamedtaki Abdulaziz Tejani
Consulting or Advisory Role - Exelixis
Speakers' Bureau - Natera
Research Funding - Bayer (Inst)
 
Melissa C Stilian
No Relationships to Disclose
 
Mathis Thoma
Employment - Leap Therapeutics
 
Michael Kagey
Employment - Diagonal Therapeutics (I); Leap Therapeutics
Stock and Other Ownership Interests - Biogen (I); Leap Therapeutics; Syros Pharmaceuticals
Patents, Royalties, Other Intellectual Property - I have patents pending and granted for discovery based work at Leap Therapeutics (current employer), Tensha Therapeutics (acquired by Roche) and the Whitehead Institute (licensed to Syros Pharmaceuticals)
 
Jason Baum
Employment - Intercept Pharmaceuticals (I); Leap Therapeutics
Stock and Other Ownership Interests - Intercept Pharmaceuticals (I); Leap Therapeutics
 
Cynthia A. Sirard
Employment - Leap Therapeutics
Leadership - Leap Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics
Patents, Royalties, Other Intellectual Property - Pending patent application;Application No. 62/260,959
Travel, Accommodations, Expenses - Leap Therapeutics
 
Rachel A Altura
Employment - Leap Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics
Travel, Accommodations, Expenses - Leap Therapeutics
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; Amgen; Arcus Biosciences; Astellas Pharma; BeiGene; BeiGene; Bristol-Myers Squibb; Geneos; Gilead Sciences; Insys Therapeutics; Merck; Novartis; SERVIER; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly